Glibenclamid failed to present amelioration of insulin resistance as seen from the relatively high insulin levels (626.3 ± 140.7 mU/L) at the end of HEGC protocol, but both metformin and pioglitazone produced an insulin-senzitizing effect (with values of 266.6 ± 72.93 and 291.5 ± 65.46 mU/L, respectively). This evidence concerns the gene INS and Insulin resistance.